Boston Scientific Corp (BSX)vsEdwards Lifesciences Corp (EW)
BSX
Boston Scientific Corp
$69.48
-0.59%
HEALTHCARE · Cap: $103.56B
EW
Edwards Lifesciences Corp
$82.50
+0.05%
HEALTHCARE · Cap: $48.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 231% more annual revenue ($20.07B vs $6.07B). EW leads profitability with a 17.7% profit margin vs 14.4%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
EW
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.0%
Fair Value
$70.62
Current Price
$69.48
$1.14 discount
Margin of Safety
-537.7%
Fair Value
$12.44
Current Price
$82.50
$70.06 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Strong operational efficiency at 23.7%
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
BSX profiles as a growth stock while EW is a mature play — different risk/reward profiles.
EW carries more volatility with a beta of 0.93 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 53/100) and 15.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?